European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
- 1 May 2009
- journal article
- recommendations
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (5) , 629-634
- https://doi.org/10.1136/ard.2008.095299
Abstract
Objective: To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail. Methods: In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate. Results: In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert’s experience. Conclusions: This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.Keywords
This publication has 14 references indexed in Scilit:
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patientsAnnals of the Rheumatic Diseases, 2007
- Evidence-Based Medicine (EBM) in Practice: Applying Number Needed to Treat and Number Needed to HarmAmerican Journal of Gastroenterology, 2005
- Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group databaseAnnals of the Rheumatic Diseases, 2005
- EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committeesAnnals of the Rheumatic Diseases, 2004
- Prevalence of systemic sclerosis in a French multi-ethnic countyRheumatology, 2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- A general parametric approach to the meta‐analysis of randomized clinical trialsStatistics in Medicine, 1991
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980